Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Pliant Therapeutics Announces Positive Long-Term Data from
Bexotegrast was well tolerated up to 40 weeks of treatment with…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Pliant
Pliant Therapeutics Announces FDA Clearance of
<!-- Name:DistributionId Value:8741346 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Pliant Therapeutics Announces Closing of Upsized Public
<!-- Name:DistributionId Value:8738063 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Pliant Therapeutics Announces Pricing of Upsized $250.0
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today…
Pliant Therapeutics Announces Positive Data from the
Bexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No bexotegrast-treated patients experienced disease progression as defined by FVCpp decline of greater…